Teva announced yesterday that a new version of Copaxone met its goals in a late-stage clinical trial. MSers who took the newer version of glatiramer acetate were ~34% less likely to have a relapse of their symptoms over the course of a year compared to MSers who took placebo. Copaxone is injected once a day, and the new version needs to be taken only 3x a week. Teva said the late-stage trial involved around 1,400 MSers.
Oh, so they are trying to sell the old stuff, with some "modifications" for PR reasons methinks. I wonder if anyone is going to take injectables which are not terrifically effective either once oral medications get off the ground.
An extremely valid comment!
maybe they wiill come up with a X1 study in a decade or so once the liofe of the X3 runs out:-)